News

China Said Covid Death Toll In Hospitals Is On A Downward Trend

-South China Morning Post https://www.scmp.com/news/china/science/article/3207987/china-says-covid-death-toll-hospitals-downward-trend?module=live&pgtype=homepage

byCharles Gross

January 25, 2023

1 minute read

-South China Morning Post

https://www.scmp.com/news/china/science/article/3207987/china-says-covid-death-toll-hospitals-downward-trend?module=live&pgtype=homepage

Legal
News

Vyne Therapeutics Granted U.S. Patent Titled ‘Wax foamable vehicle and pharmaceutical compositions thereof’

By Benzinga Newsdesk

August 31, 9:58 AM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6690&f=G&l=50&d=PTXT&p=134&S1=20210831&OS=20210831&RS=20210831

VYNE

Tempest Enters Into Exclusive License Agreement With The University Of California For Novel Cancer Target

By Bill Haddad

September 13, 8:07 AM

Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that it has

TPST

30 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

September 8, 12:02 PM

Gainers Kadmon Holdings, Inc. (NASDAQ: KDMN) shares jumped 72.6% to $9.15. Sanofi announced Wednesday it has agreed to acquire New York-based biopharma Kadmon in a $1.9 billion all-cash deal.

ALEC

SVB Leerink Maintains Outperform on Bruker, Raises Price Target to $85

By Benzinga Newsdesk

February 14, 5:31 AM

SVB Leerink analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $84 to $85.

BRKR

China Said Covid Death Toll In Hospitals Is On A Downward Trend

Related Posts

Vyne Therapeutics Granted U.S. Patent Titled ‘Wax foamable vehicle and pharmaceutical compositions thereof’

Tempest Enters Into Exclusive License Agreement With The University Of California For Novel Cancer Target

30 Stocks Moving In Wednesday’s Mid-Day Session

SVB Leerink Maintains Outperform on Bruker, Raises Price Target to $85